Shattuck Labs (STTK) closed at $5.05 on November 11, 2026, up 4.1% from the previous close, on volume of 947,619 shares (30-day average 1,158,828).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Straddle or Synthetic | 20-Nov-266 C : 6 P | 1,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 6:10 AM ET)
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Globe Newswire (Thu, 1-Oct 7:00 AM ET)
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Globe Newswire (Wed, 2-Sep 4:05 PM ET)
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Tue, 11-Aug 6:15 AM ET)
SL-325 Shows Promising Safety and Durability in Phase 1, Setting Stage for Crohn’s Disease Trial
Market Chameleon (Mon, 8-Jun 3:06 AM ET)
Market Chameleon (Fri, 6-Mar 6:09 AM ET)
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Shattuck Labs trades on the NASDAQ stock market under the symbol STTK.
As of November 11, 2026, STTK stock price climbed to $5.05 with 947,619 million shares trading.
STTK has a beta of 0.50, meaning it tends to be less sensitive to market movements. STTK has a correlation of 0.01 to the broad based SPY ETF.
STTK has a market cap of $514.30 million. This is considered a Small Cap stock.
Last quarter Shattuck Labs reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-90,000 and missed earnings estimates by -$.04.
In the last 3 years, STTK traded as high as $11.76 and as low as $.69.
The top ETF exchange traded funds that STTK belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
STTK has outperformed the market in the last year with a return of +167.2%, while the SPY ETF gained +12.6%. However, in the most recent history, STTK shares have underperformed the stock market with its stock returning -29.3% in the last 3 month period and -12.5% for the last 2 week period, while SPY has returned -1.5% and -1.3%, respectively.
STTK support price is $4.59 and resistance is $5.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STTK shares will trade within this expected range on the day.